Diabetic Medication for Endocrine/Metabolic: 75.3% of denials overturned
In 263 California IMR decisions from 2017 to 2025, reviewers overturned 198 (75.3%). In the last five years: 78.3% of 217. 245 were medical-necessity disputes, 18 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 11 | 100.0% |
| 2022 | 12 | 83.3% |
| 2023 | 45 | 77.8% |
| 2024 | 64 | 68.8% |
| 2025 | 85 | 82.4% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 76 | 77.6% | 75.3% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 36 | 63.9% | 75.3% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 28 | 50.0% | 75.3% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 26 | 61.5% | 75.3% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 21 | 71.4% | 75.3% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 19 | 0.0% | 75.3% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 13 | 53.8% | 75.3% |
| Urgent or emergencyThe findings mention urgency. | 3 | 100.0% | 75.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Ozempic. In this case, the patient has a qualifying HbA1c that meets the criteria for a diagnosis of type 2 diabetes mellitus (DM) with a most recent hemoglobin A1c (HbA1c) of an elevated value. The patient was previously on Ozempic with a documented good response, but the …”
“The physician reviewer found that a patient has requested authorization and coverage for Ozempic. The U.S. Food and Drug Administration (FDA) has approved Ozempic to improve blood sugar levels in patients with type 2 diabetes. Medical literature shows that Ozempic has demonstrated improvements in blood sugar control and weight reduction compared to placebo. In this case, the patient presents with …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Fiasp. In this case, the patient has been diagnosed with type 2 diabetes mellitus (DM) and requires intensive insulin therapy. The patient’s treatment regimen was comprised of Fiasp. For this patient, pharmacodynamic differences are clinically significant, as they may increase the risk …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for Ozempic. Ozempic (semaglutide) is a U.S. Food and Drug Administration approved medication for glycemic control in adults with type 2 diabetes and for reduction of cardiovascular risk in appropriate patients. It is not approved for use in patients with type 1 diabetes. Current …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Diabetic Medication denials for Endocrine/Metabolic overturned?
In 263 California IMR decisions from 2017 to 2025, reviewers overturned 198 (75.3%). In the last five years: 78.3% of 217. 245 were medical-necessity disputes, 18 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.